PAVmed Inc
PAVM0.363USD
-0.013-3.48%
Market hours （ET）Quotes delayed by 15 min
7.31MMarket Cap
0.10P/E TTM
More Details of PAVmed Inc Company
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
PAVmed Inc Info
Ticker SymbolPAVM
Company namePAVmed Inc
IPO dateJul 27, 2016
CEODr. Lishan Aklog, M.D.
Number of employees39
Security typeOrdinary Share
Fiscal year-endJul 27
Address360 Madison Avenue
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10017
Phone12129494319
Websitehttps://pavmed.com/
Ticker SymbolPAVM
IPO dateJul 27, 2016
CEODr. Lishan Aklog, M.D.
Company Executives of PAVmed Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
228.72K
--
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
226.67K
-2.16%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
215.00K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
200.83K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
162.19K
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Baxter
Mr. Timothy (Tim) Baxter
Independent Director
Independent Director
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
228.72K
--
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
226.67K
-2.16%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
215.00K
--
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
200.83K
--
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
162.19K
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Oct 7
Updated: Tue, Oct 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tasso Partners, LLC
9.17%
Sargent Investment Group, LLC
3.58%
First Manhattan Co. LLC
2.54%
Dubreville (Anthony Michael)
2.16%
Pavilion Venture Partners, L.L.C.
1.06%
Other
81.49%
Shareholders
Shareholders
Proportion
Tasso Partners, LLC
9.17%
Sargent Investment Group, LLC
3.58%
First Manhattan Co. LLC
2.54%
Dubreville (Anthony Michael)
2.16%
Pavilion Venture Partners, L.L.C.
1.06%
Other
81.49%
Shareholder Types
Shareholders
Proportion
Corporation
13.52%
Individual Investor
11.24%
Investment Advisor
9.64%
Investment Advisor/Hedge Fund
0.57%
Research Firm
0.27%
Hedge Fund
0.16%
Other
64.60%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
89
2.26M
8.05%
+439.12K
2025Q2
101
5.16M
29.26%
+2.76M
2025Q1
106
5.16M
31.74%
+3.03M
2024Q4
110
2.41M
17.67%
+156.53K
2024Q3
120
2.58M
24.42%
+197.13K
2024Q2
133
1.94M
20.61%
-301.78K
2024Q1
169
2.19M
26.52%
+433.78K
2023Q4
185
1.60M
20.86%
-48.73K
2023Q3
208
1.30M
18.00%
-268.87K
2023Q2
221
1.26M
18.65%
-731.24K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Tasso Partners, LLC
2.57M
12.12%
+2.57M
--
Feb 21, 2025
Sargent Investment Group, LLC
1.01M
4.74%
+1.01M
--
Jul 01, 2025
First Manhattan Co. LLC
714.10K
3.36%
--
--
Jun 30, 2025
Dubreville (Anthony Michael)
606.26K
2.85%
+606.26K
--
Aug 30, 2024
Pavilion Venture Partners, L.L.C.
297.11K
1.4%
--
--
Apr 22, 2025
Aklog (Lishan)
228.72K
1.08%
+150.00K
+190.54%
Sep 30, 2025
Glennon (Michael J)
231.67K
1.09%
+150.00K
+183.67%
Sep 30, 2025
White (Debra Jayne)
215.00K
1.01%
+150.00K
+230.77%
Sep 30, 2025
Sparks (Ronald M)
215.00K
1.01%
+150.00K
+230.77%
Sep 30, 2025
Baxter (Timothy E)
215.00K
1.01%
+150.00K
+230.77%
Sep 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Date
Type
Ratio
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
Dec 04, 2023
Merger
15→1
